Reimbursement Deal In Germany Puts Forxiga Back On Medicine Menu
This article was originally published in The Pink Sheet Daily
Executive Summary
A deal struck between Germany’s health insurance funds and Astra Zeneca/Bristol Myers Squibb means the drug manufacturers are ready to start supplying the drug again to the country’s health service.
You may also be interested in...
Germany’s Grand Coalition Offers Pharma Little Certainty, Except For Continued Discounts
Germany’s new grand coalition government includes a health minister with no background in health care.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.